secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-003555
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.03, 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Bio closes $31M royalty financing liability with HCR Molag Fund
---------------------------------------------------------------------

- Closed $31M royalty financing with HCR Molag Fund on Dec 30, 2022; recorded net of transaction costs.
- Financing stems from Purchase and Sale Agreement dated Dec 20, 2022, previously disclosed.
- Transaction creates a direct financial obligation under Item 2.03 of Form 8-K.
- HCR Molag Fund, L.P. is the counterparty; net proceeds used for general corporate purposes (not specified).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/0001193125-23-003555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523003555/d444758d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-003555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer